New Technique Appears Effective In Predicting Progression To Alzheimer’s Disease
June 17, 2009
Adapted from the University of California - San Diego
Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI—which measures the "memory centers" of the brain and compares them to expected size—is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. The procedure can be readily used in clinics to measure brain atrophy, and may help physicians to predict decline in MCI patients. Their study has been published in the June issue of the journal Alzheimer Disease and Associated Disorders.
"Use of this procedure is like bringing the experience of an expert neuro-radiologist to any clinic that has the right software," said James Brewer, M.D., Ph.D., assistant professor in UC San Diego's Departments of Radiology and Neurosciences. "These fully automated and rapid methods of measuring medial temporal lobe volumes may help clinicians predict cognitive decline in their patients, and have the potential to influence how neurology is practiced."
Mild cognitive impairment (MCI) is considered a transitional stage between the forgetfulness associated with normal aging and Alzheimer's disease. Yet, many patients with MCI do not progress to Alzheimer's, and these individuals don't need treatments targeted to prevent or slow down neuro-degeneration. Therefore, objective measures are necessary to distinguish MCI patients who will clinically decline from those who will remain stable.
"Our goal was to find neuroimaging measures of change that reflected more than merely a person's advancing age, but instead correlated tightly with how a person's cognitive status worsens over time," said co-author Michael Rafii, M.D., Ph.D., assistant professor of neurosciences at UC San Diego. "It's too early to draw a definitive comparison, but it appears that these early changes—especially shrinking of the hippocampus - may offer a robust biological marker for change." Medial temporal lobe atrophy has been associated with increased risk for conversion of MCI to Alzheimer's disease. However, until now, studies have focused only on measurements of the brain's hippocampus. The extent to which volumes of the amygdala—the section of the brain associated with emotions—and the nearby temporal horn could predict cognitive decline was unknown.
In addition, methods to measure these parts of the brain relied on subjective assessments of MRIs using a "tracing technique" that literally required a drawing of these portions of the brain – a technique that isn't practical or possible in most clinical settings.
For more than a year, researchers at the Memory Disorders Clinic at UC San Diego Medical Center have been successfully using a fully computerized procedure that takes images from the MRI scanner and translates them into quantitative values, according to Rafii, the clinic's director. UC San Diego was the first clinic site to use this technology, which is now starting to be used in other clinical settings throughout the country.
"These values objectively measure the hippocampus and amydala, and early data confirm previous findings that these brain areas may atrophy early in Alzheimer's disease and can offer a clinical marker for change," said Rafii. The fluid-filled temporal horn increases as the hippocampus shrinks, and these complementary measurements may correlate closely with how a patient's cognitive status worsens over time, he added.
View all news updates for Alzheimer's disease
Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.